Does insulin pump therapy offer benefits for behaviour, mood, cognition and HbA1c in children and adolescents with type 1 diabetes? A randomised controlled trial with observational follow-up.
Michele A O'ConnellElisabeth A NorthamAmy BrownJennifer PapoutsisTibor SchusterTimothy SkinnerAlicia J JenkinsGeoffrey R AmblerMichele A O'ConnellPublished in: Archives of disease in childhood (2024)
Parent-reported behaviour problems and HbA1c, but not mood or neurocognitive outcomes, were clinically significantly lower with CSII, relative to MDI, after 4 months. Observational follow-up indicated no impact of treatment modality at +2 years, relative to baseline levels. Taken together, these data indicate that use of CSII alone does not comprehensively benefit neuropsychological outcomes in childhood T1D.
Keyphrases
- bipolar disorder
- mild cognitive impairment
- type diabetes
- mental health
- glycemic control
- sleep quality
- cross sectional
- electronic health record
- big data
- machine learning
- white matter
- depressive symptoms
- multiple sclerosis
- artificial intelligence
- young adults
- skeletal muscle
- bone marrow
- combination therapy
- data analysis
- childhood cancer